Folkers K, Langsjoen P, Langsjoen P H
Institute for Biomedical Research, University of Texas, Austin 78712.
Biochem Biophys Res Commun. 1992 Jan 15;182(1):247-53. doi: 10.1016/s0006-291x(05)80137-8.
Twenty years of international open and seven double blind trials established the efficacy and safety of coenzyme Q10 (CoQ10) to treat patients in heart failure. In the U.S., ca. 20,000 patients under 65 years are eligible for transplants, but donors are less than 1/10th of those eligible, and there are many more such patients over 65, both eligible and ineligible. We treated eleven exemplary transplant candidates with CoQ10; all improved; three improved from Class IV to Class I; four improved from Classes III-IV to Class II; and two improved from Class III to Class I or II. After CoQ10, some patients required no conventional drugs and had no limitation in lifestyle. The marked improvement is based upon correcting myocardial deficiencies of CoQ10 which improve mitochondrial bioenergetics and cardiac performance. These case histories, and very substantial background proof of efficacy and safety, justify treating with CoQ10 patients in failure awaiting transplantation.
历经20年的国际开放试验和7项双盲试验证实了辅酶Q10（CoQ10）治疗心力衰竭患者的有效性和安全性。在美国，约20000名65岁以下的患者符合移植条件，但供体人数不到符合条件者的十分之一，而且65岁以上符合条件和不符合条件的此类患者更多。我们用CoQ10治疗了11名典型的移植候选者；所有人的病情都有所改善；3人从IV级改善到I级；4人从III-IV级改善到II级；2人从III级改善到I级或II级。服用CoQ10后，一些患者不再需要常规药物，生活方式也没有限制。显著的改善是基于纠正CoQ10的心肌缺乏，这改善了线粒体生物能量学和心脏功能。这些病例记录以及非常充分的有效性和安全性背景证据，证明了用CoQ10治疗等待移植的心力衰竭患者是合理的。
